TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial of the Treatment of Chronic Laryngitis With Amitryptiline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older and able to consent for themselves.~* Structural pathology such as tumor previously ruled out using flexible laryngoscopy.~* Able to speak and read the English language.~* Failed a trial of a proton pump inhibitor for the treatment of gastopharyngeal reflux.~* Women under 55 years of age who may become pregnant must have a negative pregnancy test and agree to barrier or hormonal methods of contraception during the study.~Exclusion Criteria:~* Environmental allergies.~* Smoking within past 5 years.~* Using ginko bilboa (or unwilling to cease using it).~* Current upper respiratory infections.~* Use of narcotics (e.g. oxycodone, methadone).~* Any prior history of amitryptiline use.~* Use of monoamine oxidase inhibitors (MAOIs) within the past 4 weeks (selegiline, phenelzine, tranylcypromine, isocarboxazid, rasagiline, phenelzine sulfate, selegiline hydrochloride, rasagiline mesylate, tranylcypromine sulfate).~* History of urinary retention.~* Any history of major depressive disorder.~* Any prior history of allergy to a tricyclic antidepressant.~* Current diagnosis of gastroesophageal reflux (GERD).~* For women 18-55 years of age without history of menopause: currently nursing or pregnant, plans to become pregnant, or unwillingness to utilize contraception (barrier or hormonal methods).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- amitriptyline (Type: EXPERIMENTAL): Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in this arm will receive pills composed only of Avicel (cellulose filler)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients scheduled for open elective major abdominal surgery and expected to last a minimum of 2 hours will be included in the study.~(Major abdominal surgery includes all gynecological, urological and general surgical operations requiring laparotomy)~Exclusion Criteria:~* Patients younger than 18 years of age~* Patients unable to give informed consent~* Pregnancy or breastfeeding~* Patients transferred form the intensive care unit to the operating theater~* Patients with an already established catecholamine therapy~* Emergency operation~* Chronic inflammatory diseases (chronic inflammatory rheumatoid diseases, chronic inflammatory renal diseases, chronic inflammatory infectious diseases, chronic inflammatory bowel diseases, chronic liver disease with signs of liver insufficiency)~* Severe cardiovascular disease (heart disease with an ejection fraction below 30%, instable coronary syndromes, severe valvular disease)~* Any signs of infection or sepsis~* Any contraindication for oesophageal Doppler monitoring (oesophageal and aortic pathology, planned oesophageal resection)~* Renal insufficiency with a glomerular filtration rate below 30ml/min~* Patients with additional epidural anesthesia are excluded from the study if epidural anesthesia is planned to be used for analgesia intraoperatively

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NaCl 0.9% BBraun (normale saline) (Type: ACTIVE_COMPARATOR): 154mmol/l sodium, 154mmol/l chloride
- Elo-Mel Isoton (balanced acetat-based infusate) (Type: ACTIVE_COMPARATOR): sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients who are functionally anuric (urine volume \<100ml/day)~* receiving chronic maintenance dialysis for treatment of end-stage renal disease~* transitioning from hemodialysis (HD) to peritoneal dialysis (PD)~* transitioning from PD to HD~* receiving PD and have a functional arteriovenous access already in place~Exclusion Criteria:~* \< 18 years of age~* anticipate living related kidney transplant or transfer of care away from a participating unit within the next 6 months~* have anticipated survival \<6 months~* have contraindications to PD therapy~* history of complicated bowel or abdominal aortic surgery~* known abdominal wall defects~* pregnancy (including pre-menopausal women not surgically sterilized or on hormonal contraception)~* indwelling trans-abdominal prosthetic devices (e.g., feeding or biliary tubes)~* known hypersensitivity to peritoneal dialysate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- icodextrin-based peritoneal dialysis to hemodialysis (Type: OTHER): 12-week course of adjuvant low-frequency icodextrin-based peritoneal dialysis to ongoing thrice-weekly maintenance hemodialysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EndoFLIP Use in Upper GI Tract Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \> or = to 18 years of age~* Referred for evaluation and treatment of benign esophageal luminal narrowing~* Clinical diagnosis of benign esophageal luminal narrowing with documentation and imaging~* Adult patients with benign refractory esophageal strictures referred for placement of an esophageal stent are eligible for this study~* Willing and able to give informed consent~* No condition or comorbidity which would prevent the patient from undergoing a successful upper endoscopy~Exclusion Criteria:~* \< 18 years of age~* Pregnancy~* History of prior endoscopic dilation\* (\*unless referred for placement of stent)~* Coagulopathy~* Inability to traverse the stricture using standard techniques~* Patients unable to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EndoFLIP Measurements (Type: None): To define the role of a functional luminal imaging probe (EndoFLIP) in benign upper GI luminal narrowing. EndoFlip measurement of the cross sectional area of the narrowing will be obtained prior to and after endoscopic dilation. Patients will follow up for repeat endoscopy and dilation if indicated. EndoFLIP measurements will be made again before and after dilation. The use of EndoFlip may offer insight in to the clinical and endoscopic predictors of successful stricture dilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Neuro-HAART in Patients With HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV positive with nadir cluster of differentiation 4 (CD4) count \<350 /microlitre (uL)~* Taking HAART with CNS Penetration Effectiveness (CPE) score of either ≤7.0 or ≥7.5 for 1 year or more. Changes in antiretrovirals (ARVs) within the last 12 months are allowed so long as the CPE score does not lead to a change groups~* Plasma HIV viral load \<50 copies / mL for preceding 12 months or longer~* Informed consent given by participant or legally appointed guardian~Exclusion Criteria:~* Non-HIV related neurological disorders and active CNS opportunistic infection as assessed by full blood count, electrolytes, creatinine, glucose, liver function tests, cryptococcal antigen, venereal disease reaction level (VDRL), MRI brain scan and cerebrospinal fluid analyses for cell count, protein, glucose, culture, VDRL and cryptococcal antigen.~* Psychiatric disorders on the psychotic axis, current major depression, and current substance use disorder as assessed by the Study Enrolment Questionnaire for Eligibility~* Severe substance use disorders (within 12 months of study entry)~* Active Hepatitis C virus (HCV) (detectable HCV RNA because HCV per se can cause cognitive impairment)~* History of loss of consciousness \>1 hour~* Non-proficient in English as assessed by the English as a second language questionnaire~* Medications known pharmacologically to interact with ARVs~* Pregnancy as assessed by the urinary pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non Neuro-HAART (low CNS penetrance) (Type: None): Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
- Neuro-HAART (high CNS penetrance) (Type: None): Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Effect of Acupressure on Shivering During a Cesarean Delivery in Women Who Were Previously Laboring With an Epidural

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a patient has to be classified as an American Society of Anesthesiology (ASA) physical status I, II, or III, laboring with an epidural catheter, and subsequently taken for a non-emergent cesarean section under epidural anesthesia with a core body temperature range of 35.5-38.0 degrees Celsius during shivering.~Exclusion Criteria:~* ASA status 4 or higher~* core body temperature lower than 35.5 or higher than 38.0~* thyroid disease~* systemic infection~* emergent cesarean section,~* a psychiatric, cognitive or medical condition that would compromise adherence to the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Sham bracelet (Type: PLACEBO_COMPARATOR): Patients randomized to sham group will wear bracelets on both hands which will not apply acupressure
- Acupressure bracelet (Type: EXPERIMENTAL): Patients randomized to the experimental group will wear bracelets on both hands which will apply acupressure to the P6 acupoint.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Of Chronic Anal Fissure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Danish citizens, age ≥ 18 years~2. Presence of a midline anal fissure, dorsal or ventral~3. Pain during and after defecation lasting for more than 8 weeks~4. Presence of a sentinel anal tag or hypertrophic papilla~5. Exposure of the horizontal fibres of the internal anal sphincter~1-3 has to be fulfilled for inclusion. Additionally 4 AND/OR 5 has to be present~Exclusion Criteria:~1. Inflammatory bowel disease, known venereal disease, immunodeficiency disease~2. Anal/perianal abscess~3. Anal or rectal surgery within 12 weeks~4. Pregnancy or breastfeeding females~5. History of migraine or chronic headache requiring treatment with analgetics~6. Any cardiovascular or cerebrovascular disease~7. Current use of calcium channel blockers in general or history of use of calcium channel blockers in the treatment of the fissure~8. Signs of other rectal diseases, fistula, infection including severe perianal eczema and tumours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diltiazem, calcium channel blocker (Type: ACTIVE_COMPARATOR): Diltiazem gel 2% applied twice daily for 8 weeks
- Levorag, Hibiscus plant extract (Type: EXPERIMENTAL): Levorag Emulgel applied twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluoxetine for Visual Recovery After Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MRI-confirmed acute ischemic stroke resulting in an isolated homonymous visual field loss.~Exclusion Criteria:~* Known hypersensitivity to fluoxetine or other selective serotonin reuptake inhibitors~* National Institutes of Health Stroke Scale score greater than 5~* Premorbid modified Rankin Scale score greater than 2~* Premorbid monocular or binocular visual field deficits~* Premorbid retinopathy or optic neuropathy~* Premorbid depression~* History of cognitive impairment, dementia, or neurodegenerative disorder~* History of seizure disorder~* History of mania or hypomania~* History of hyponatremia~* History of angle-closure glaucoma or elevated intraocular pressure~* Current alcohol abuse or impaired liver function~* Current use of an antidepressant medication~* Current use of a medication likely to have an adverse interaction with fluoxetine~* Current use of a medication likely to impair post-stroke recovery~* Contraindication to MRI~* Pregnancy or lactation~* Hemorrhagic transformation of the index stroke, resulting in mass effect~* Enrollment in another clinical trial at the time of the index stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine (Type: EXPERIMENTAL): 20 mg fluoxetine capsule by mouth once daily for 90 days
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with diagnosis of mild AD~Exclusion Criteria:~* Concomitant or previous treatment by acetylcholinesterase inhibitors and/or memantine~* Medical condition which may interfere with the study~* History of epileptic seizures~* Lens opacity~* Lack of reliable caregiver~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): dose 1
- 2 (Type: EXPERIMENTAL): dose 2
- 3 (Type: EXPERIMENTAL): dose 3
- 4 (Type: PLACEBO_COMPARATOR): None
- 5 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Previously Placed Nephrostomy Tract (NT) Versus Single Stage Percutaneous Nephrolithotomy (PCNL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 years to 90 years old,~* Patients with stone disease~* Patients who hoose to have PCNL for treatment~* Patients who understand the informed consent~Exclusion Criteria:~* Minors~* Unable to understand the informed consent~* Unwilling to fill out the SF 36 questionnaire

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- NT prior to PCNL (Type: EXPERIMENTAL): A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one week prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~1. Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~2. If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol.
- NT at the surgery (Type: NO_INTERVENTION): A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Modification and Validation of the RIPASA Score for Diagnosis of Acute Appendicitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all consecutive patients age ≥ 16 years, who are referred to the on-call surgeon's team with acute right iliac fossa (RIF) pain or suspected acute appendicitis, will be included.~Exclusion Criteria:~* history of previous appendicectomy~* previous abdominal surgery in the last 90 days~* history of chronic abdominal pathology (e.g. ovarian cyst, colitis .. etc)~* history of inguinal hernia~* pregnancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- African (Type: None): patients originating from Nigeria and Sudan (11 centres)
- Latin American (Type: None): patients originating from Mexico (5 centres)
- South Asian (Type: None): patients originating from India and Pakistan (10 centres)
- European (Type: None): patients originating from Spain (11 centres).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma Using USPIO MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* High index of suspicion of locally resectable or borderline resectable pancreatic or periampullary (= duodenal, papilla of Vater or distal bile duct) cancer~* Signed and dated informed consent~Exclusion Criteria:~* Pregnancy~* Previous pancreatic surgery~* Previous treatment for the pancreatic or periampullary cancer~* Contraindications for 3T MRI~* Contraindications for USPIO based contrast agents (allergy, hereditary hemochromatosis, thalassemia, sickle cell anemia)~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- USPIO-enhanced MRI (Type: EXPERIMENTAL): Ferumoxtran-10 contrast will be intravenously administered 24-36 before performing an MRI scan. The MRI scan will be discussed with the surgeon prior to resection. Findings on MRI will be compared to pathology.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility